NSWRC(SH:600165) Xin Lang Cai Jing·2025-12-12 07:39Group 1 - The actual controller of *ST Ningke has changed, with Hunan Xinhong New Biological Pharmaceutical Co., Ltd. becoming the controlling shareholder, holding 357 million shares, which is 22.10% of the total share capital after the capital reserve conversion [1][4] - The company will implement a capital reserve conversion plan, increasing the total share capital from 685 million shares to 1.616 billion shares by converting 931 million shares, with 883 million shares allocated for introducing restructuring investors and 48.03 million shares for debt compensation [4][5] - Investors who purchased shares between November 22, 2022, and April 5, 2023, and sold or held them after April 6, 2023, or those who buy between April 28, 2023, and October 30, 2024, are eligible to participate in compensation claims [1][4] Group 2 - In 2022, the company inflated its operating income by 76.5941 million yuan and its total profit by 77.222 million yuan, accounting for 11.25% and 46.59% of the respective totals, leading to false records in the annual report [2][4] - The company failed to timely disclose significant events, including major debts and the suspension of its subsidiary's main business [2][4] - The successful restructuring of the company may benefit investor claims, although previous financial fraud has caused significant losses that investors should be aware of [5]